The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-EU loses bid for speedier AstraZeneca vaccine deliveries

Fri, 18th Jun 2021 14:06

(Recasts, adds details)

By Francesco Guarascio and Alistair Smout

BRUSSELS/LONDON, June 18 (Reuters) - AstraZeneca will have
to deliver fewer COVID-19 vaccines to the European Union than
the bloc had hoped after Brussels lost its bid to speed up
deliveries on Friday, in the first of its legal actions against
the drugmaker.

AstraZeneca said that the EU had lost its legal
case, but European Commission President Ursula von der Leyen
said the court ruling supported its view that the Anglo-Swedish
pharmaceutical giant had failed to honour its commitments.

The row plunged the EU into crisis earlier this year as
states scrambled for shots, highlighting the pressure on them to
speed up vaccinations. Brussels has since largely cut ties with
AstraZeneca, choosing not to buy any more of its shots for now.

The drugmaker had committed to do its best to deliver 300
million doses to the 27-nation bloc by the end of June, but
production delays led it to revise this to 100 million vaccines.

This delayed the EU's vaccination drive as the bloc had
initially bet on AstraZeneca to deliver the largest volume of
its shots, sparking a bitter row and EU legal action to get at
least 120 million doses by the end of June.

However, the judge ruled that AstraZeneca must deliver only
80.2 million doses by a deadline of Sept. 27. The drugmaker said
it would "substantially exceed" that by the end of June.

The court said in a statement that AstraZeneca must deliver
15 million doses by July 26, another 20 million by Aug. 23 and a
further 15 million by Sept. 27, to reach a total of 50 million
doses, which are in addition to 30 million that had already been
given to the EU when the legal case began.

Should it miss the deadlines in the ruling, AstraZeneca
would face a penalty of "10 euros ($11.8) per dose not
delivered", the Commission said, less than the 10 euros per dose
per day fine it had sought in bringing its legal action.

AstraZeneca will remain bound to do its best to deliver 300
million doses to the EU, without a precise timetable, and a new
hearing could be held in September if it failed to do so, an EU
lawyer told a news conference.

BRITISH DOSES

The lawyer also said the judgment meant that as a proof of
best effort AstraZeneca will have to deliver COVID-19 vaccines
from a factory in Britain, if needed to meet its EU commitments.

The company had said it could not immediately deliver to the
EU doses from an Oxford Biomedica factory because it had to
supply Britain first.

AstraZeneca said other measures sought by the Commission had
been dismissed and the court had found that the EU had no
exclusivity or right of priority over other parties.

"The judgment also acknowledged that the difficulties
experienced by AstraZeneca in this unprecedented situation had a
substantial impact on the delay," it said in a statement.

"AstraZeneca now looks forward to renewed collaboration with
the European Commission to help combat the pandemic in Europe."

The EU last month launched a second legal action against
AstraZeneca over an alleged breach of the supply contract, which
will continue after the summer. Friday's ruling was over whether
AstraZeneca had to speed up vaccine deliveries.
(Reporting by Francesco Guarascio in Brussels, Alistair Smout
in London, additional reporting by Muvija M in Bengaluru;
Editing by David Evans, Catherine Evans. Louise Heavens and
Alexander Smith)

More News
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.